What is the current stock price of Biogen Inc. (BIIB)?

As of the latest market data, Biogen Inc. (BIIB) is trading at $193.76. The stock has seen a gain of 2.26% today.

Does Biogen Inc. (BIIB) pay a dividend?

Based on current data, Biogen Inc. does not have a confirmed active dividend policy.

What is the market cap of Biogen Inc.?

The current market capitalization of Biogen Inc. (BIIB) is approximately unavailable.

BIIB

Biogen Inc.·Healthcare

193.76

2.264%(+4.29)

Market Closed

199.99

3.215%(+6.23)

After Hours

Last Updated: — ET

52W L: $121.0552W H: $205.97

BIIB NEWS

zacks.com

1d ago

Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails

DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.

prnewswire.com

1d ago

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for diranersen missed its primary endpoint -- wiping out billions in market value. NEW YORK, May 22, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) investors lost approximately 6.4% per share on May 14, 2026, when the company disclosed that its Phase 2 "CELIA" trial for diranersen (BIIB080) failed to meet its primary dose-response endpoint in early Alzheimer's disease.

marketbeat.com

1d ago

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

U.S. Food & Drug Administration (FDA) events crystallize the risk/reward thesis for many biotechnology stocks, and Biogen Inc.'s NASDAQ: BIIB latest Alzheimer's update shows why that trade can turn quickly.

prnewswire.com

1d ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

reuters.com

1d ago

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

Biogen and Denali Therapeutics said on Thursday they will discontinue development of ‌their Parkinson's drug after it failed to meet the main goal in a mid-to-late stage study.

globenewswire.com

1d ago

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson's disease. Results from the study show that BIIB122 did not slow the progression of Parkinson's disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson's disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant.

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

7,605

IPO Date

1991-09-17

Beta

0.20

Websitewww.biogen.com↗